A U.S. District Judge declined to rule on a pair of motions filed by GSK defense lawyers, meaning the drugmaker will head to court to face claims that a generic version of its Paxil antidepressant caused an Illinois man's suicide.
In July 2010, attorney Stewart Dolin stepped in front of an oncoming Chicago train. An autopsy confirmed the presence of a generic version of GSK’s antidepressant Paxil.
The trial, scheduled for September, will be GSK's first over suicide claims in an adult. The complaint accuses GSK of failing to include a warning on Paxil’s labeling that the drug has ties to suicidal behavior in adults.
The suit initially included claims against Mylan -- the manufacturer of the generic Paxil -- however, claims were dismissed in 2014, because generic drugmakers have been required by the FDA to duplicate official branded labeling, making the branded pharmas responsible.
Read the American Lawyer coverage